Building and Validating Oncosimulators and Oncosimulator Based - - PowerPoint PPT Presentation

G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 1

Georgios S. Stamatakos

In Silico Oncology and In Silico Medicine Group, Institute of Communication and Computer Systems, School of Electrical and Computer Engineering, National Technical University of Athens, Greece & Medical School, University of Saarland, Germany https://www.in-silico-oncology.iccs.ntua.gr/

29 Aug. 2019

In Silico Oncology: Building and Validating Oncosimulators and Oncosimulator Based Hypermodels as Clinical Decision Support Systems

Acknowledgements

• Prof. Norbert Graf is greatly acknowledged for the clinical drive, the clinical positioning, the provision of

crucial clinical data and the clinical overview of the work concerning nephroblastoma modelling, an excellent Oncosimulator development paradigm.

• All my collaborators at the In Silico Oncology & In Silico Medicine Group, (ISO&ISM_G) ICCS, SECE,

NTUA are greatly acknowledged for their enthusiasm, commitment and hard and efficient work. Special thanks are due to : Dr D. Dionysiou, Dr V. Antipas, Dr E. Kolokotroni, Dr E. Georgiadi, Dr S. Giatili, Dr E. Ouzounoglou, Ms K. Argyri, Mr N. Christodoulou, Mr C. Antonopoulos, Mr C. Kyroudis, and Mr N. T

• usert.
• Prof. Uzunoglu is duly acknowledged for his crucial encouragement and support during the initial steps
• f the endeavour.
• All partners of the 17 organizations who participated in the European Commission (EC) funded EC-US

project CHIC as well all partners involved in the Oncosimulator & Hypermodelling development and their clinical adaptation and validation for the past 22 years are greatly acknowledged for their important contributions.

• All partners involved in the Oncosimulator development and validation of the European Commission

funded projects ACGT, ContraCancrum, TUMOR, p-medicine, Dr Tharapat, MyHealthAvatar are duly acknowledged.

• All external collaborators of ISO&ISM_G since 1997 are duly acknowledged.
• The European Commission, the Greek and the German States are duly acknowledged for their crucial

financial support

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 2

The CHIC Project at a glance

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 3

The CHIC Project at a glance

• The large scale EU-US integrating research project CHIC has

been entitled: “CHIC: Developing meta- and hyper-multiscale models and repositories for in silico oncology”

• Website: http://www.chic-vph.eu/
• Funded by the European Commission with a grant of

10,582,000 €.

• Seventeen academic, research and industrial partner
• rganizations across Europe and US participated in CHIC.
• The CHIC project underwent its final review on 23 and 24

May 2017 and was assessed as "Excellent" by the Board of (five) External Reviewers appointed the European Commission.

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 4

The CHIC Project at a glance (cont.)

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 5

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 6

The CHIC Project at a glance (cont.)

The CHIC Project at a glance (cont.)

• THE CHIC PROJECT COORDINATION

SCHEME

• Overall and Scientific Coordinator: Research

Professor G. Stamatakos, ICCS-National T echnical University of Athens, Greece

• Assistant Clinical Coordinator: Professor

Norbert Graf, University Hospital of Saarland, Germany

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 7

Structure of the presentation

• A brief outline of the purpose, methods and

results

• Examples from the methods and the results
• Conclusions

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 8

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 9

A brief outline of the purpose, methods and results

Purpose of CHIC

• to develop, clinically adapt and partly clinically

validate meta- and hyper-multiscale models and repositories for in silico oncology

• to develop advanced technological cloud based

infrastructures supporting the process of hypermodel development and the clinical translation of hypermodels

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 10

Methods

• A host of clinical, experimental, mathematical,

computational and software engineering strategies, methods and techniques have been devised and/or utilized in order to both develop and test multiscale hypermodels.

• A hypermodel is a complex mathematical and

computational model consisting of more than one elementary component model.

• Each component model or “hypomodel” simulates

a crucial biological mechanism of tumour growth and response to treatment.

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 11

Methods (cont.)

• Hypomodels are connected together in

several ways dictated by the current biological and clinical knowledge.

• Both mechanistic and machine learning

based hypermodels have been developed driven by clinically relevant questions formulated by the clinical partners of the CHIC consortium.

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 12

Methods (cont.)

• The overarching idea of the project was to

exploit the accumulated quantitative experimental and clinical knowledge concerning several spatiotemporal scales of cancer biocomplexity in

• rder to produce treatment response

predictions as precise as possible based on the patient’s individual multiscale data (e.g.

– imaging – Histological – molecular, – Clinical

data

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 13

Methods (cont.)

• To this end several candidate treatment

schemes can be simulated using detailed hypermodels fed with the actual multiscale data of the patient.

• The treatment scheme performing best in silico

will serve as the optimal suggestion to the clinician to consider for their final treatment strategy decision.

• Most hypomodels or component models have been

developed by different leading cancer modelling groups participating in the CHIC project scattered across EU and US.

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 14

Methods (cont.)

• A clinician friendly technological platform for

hypermodel creation and execution (CRAF) has also been developed and successfully tested.

• Four paradigmatic cancer types have been

considered:

– nephroblastoma, – non small cell lung cancer – glioblastoma (treated with immunotharepy in conjunction with radiotherapy and chemotherapy) – prostate cancer.

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 15

Results

• Both the hypermodels and the technological

platforms developed by CHIC have been documented, disseminated and demonstrated in real time and in detail to the appointed independent scientific evaluators

• f the European Commission.
• The overall project outcome has been finally

assessed as Excellent and worth further translational development and multifaceted exploitation.

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 16

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 17

Examples from the methods and the results

Dimensions of cancer manifestation and treatment

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 18

The Oncosimulator: a functional diagram

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 19

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 20

Basic architecture of a cancer multimodeller hypermodel

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 21

Mathematics hidden behind each constituent hypomodel

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 22

Nephroblastoma

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 23

Nephroblastoma

(Part of the whole table of diagrams / nephroblastoma )

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 24

Nephroblastoma

Multiscale Cancer Modelling Paradigms

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 25

The Wilms Tumour Branch of the Oncosimulator

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 27

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 28

Chemotherapy treatment protocol. The simulated Wilms Tumour preoperative chemotherapy treatment protocol of the SIOP/ GPOH clinical trial.

• Wilms Tumour Oncosimulator:

– Tumor Free Growth

• Tumor Chemotherapy

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 29

Cytokinetic Model for Free Tumour Growth

• stem cells: cells assumed to possess unlimited proliferative potential
• limp cells: progenitor cells with limited proliferative potential
• diff cells: terminally differentiated cells

Cell Local reoxygenation Local reoxygenation Cell Disappearance Apoptosis Spontaneous apoptosis Necrosis disappearance G0 G1 S G2 M G G0 M G2 S G1 Asymmetric division DIFF STEM LIMP Symmetric division Spontaneous apoptosis After n mitoses 29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 30

Cytokinetic Model Treatment Response

• When cells are hit by chemo (treatment session) they enter a separate cell cycle at

which they remain till they are led to apoptotic death from a point of the cell cycle specified by the mechanism of action of the drug (in the case of Epirubicin S phase is considered to be that point).

chemo G1hit Shit G2hit Mhit Cell disappearance G0hit A

(Apoptosis incl. time delay)

Spontaneous apoptosis N

(Necrosis)

Cell disappearance G0 G1 S G2 M G0 chemo Mhit G2hit Shit G1hit M G2 S G1

G0hit

Asymmetric Division DIFF STEM LIMP 29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 31

Clinical Adaptation and Validation

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 32

Successful Clinical Model Adaptation

• Case 1: [1]

Highly malignant, blastemal type of tumor

Time evolution of tumor volume and selected tumor

• subpopulations. Panel A: Time evolution of tumor volume

for the four virtual scenarios of Table 1. Panels Bi and Bii, Ci and Cii, Di and Dii, Ei and Eii: Evolution over time of selected subpopulations

• f

the tumors.The chemotherapeutic scheme of Figure 2 has been

• simulated. The drug administration instants are: day 3, day

10, day 17, day 24. Day 0: first MRI data set. Day 28: second MRI data set.

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 33

Adaptation of Several Clinical Cases

No Patient Histology Risk 1 11570 Mixed Intermediate 2 11590 Mixed with focal anaplasia Intermediate 3 11627 Mixed Intermediate 4 11628 Stromal Intermediate 5 11639 Regressive Intermediate 6 11803 Stromal Intermediate 7 11813 Mixed Intermediate 8 11537 Stromal Intermediate 9 11613 Regressive Intermediate 10 11616 Stromal Intermediate 11 11714 Mixed Intermediate 12 11733 Blastemal High 13 11736 Mixed Intermediate 14 11788 Regressive Intermediate 15 11813 Mixed Intermediate 16 11823 Regressive Intermediate 17 11845 Diffuse Anaplasia High 18 11862 Epithelial Intermediate 19 11873 Mixed Intermediate 20 11881 Regressive Intermediate

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 34

Imaging & Clinical Data

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 35

Nephroblastoma Bilateral Case Imaging Data

1st Imaging Set 2nd Imaging Set 3rd Imaging Set R L R R L L DVR=90% DVL=89% DVR=94% DVL=95%

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 36

Nephroblastoma Case Clinical Data

Histopathological data

• Nephroblastomatosis consists primarily of blastemal

cells which are actively cycling.

• Therefore the initial tumour is made up mainly of stem

and LIMP (progenitor) cells and fewer differentiated and dead cells.

• Post-surgery histological data also indicated that the

remaining viable tumour was of blastemal type.

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 37

Simulation Results

Time evolution of bilateral tumour volume and selected tumour subpopulations. A: Time evolution of tumour volume for the right and left kidney under the two scenarios of table 1. B, C, D, E: Evolution over time of the proliferating, dormant, differentiated and dead population percentage of the bilateral tumor (respectively). Where: R: Right, L:Left, TT: Typical tumour, CT: clinical tumour. 29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 38

Simulated Clinical Tumors

1st I.S. 2nd I.S. 3rd I.S. Right Kidney Left Kidney

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 39

29 Aug. 2019 40

AN EXAMPLE OF USING THE GBM RADIOTHERAPY ONCOSIMULATOR

TWO RTOG STUDY 83-02 BRANCHES SIMULATED

• 1) AHF-48Gy:

accelerated hyperfractionation, 48Gy total dose, (1.6Gy twice daily to a total dose of 48 Gy)

• 2) HF-81.6Gy:

hyperfractionation, 81.6Gy total dose.(1.2Gy twice daily to a total dose of 81.6Gy)

G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology

29 Aug. 2019 41 G.S. Stamatakos - Lecture at the Korea Institute

• f Science and Technology

An MRI slice depicting a glioblastoma mutiforme. Both the clinical volume of the tumour and its central necrotic area have been

• delineated. The present case has been considered for the

preliminary checks of the simulation model.

[G.Stamatakos, D.Dionysiou, E.Zacharaki, N.Mouravliansky, K.Nikita, and N.Uzunoglu, "In Silico Radiation Oncology: Combining Novel Simulation Algorithms with Current Visualization Techniques,'' Proc. IEEE, Special Issue on "Bioinformatics: Advances and Challenges" Vol.90, No.11, November 2002, pp.1764-1777]

29 Aug. 2019 42 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology

Spatial Discretization

29 Aug. 2019 43 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology

Mesh Initialization

NBC

Equivalence Classes

29 Aug. 2019 44 G.S. Stamatakos - Lecture at the Korea Institute

• f Science and Technology

Cytokinetic Model

Cell disappearance

G1 G2 S M G0 N A RI-MAD RI-MND SA or RI-ID

The probabilities of the alternative “death paths” due to irradiation depend primarily on the type of tumour cell.

• In GBM the vast majority of cells undergoes a mitotic necrotic death.

SA: Spontaneous Apoptosis, RI-ID: Radiation-Induced Interphase Death, RI-MAD: Radiation- Induced Mitotic Apoptotic Death, RI-MND: Radiation-Induced Mitotic Necrotic Death

Simplified flow chart for the response of a single tumour cell to irradiation. Symbol explanation: αP and βP stand for the α and β parameters of the linear quadratic model for the tumour proliferating cells excluding those in phase S. The subscript S denotes cells in the DNA synthesis phase, whereas the subscript G0 denotes cells in the resting (dormant) phase G0.

YES NO

Irradiation (αP,βP ) (αS,βS ) Cell still cycling for a few (e.g. 3) cell cycles Cell lysis/apoptosis PROLIFERATING CELL Irradiation (αG0,βG0 ) G0- CELL

NO

Has oxygen and nutrient supply become adequate? LQ cell hit Cell disappearance  Tumor shrinkage Cell death products are diffused LQ cell survival LQ cell hit Cell is gradually disintegrating LQ cell survival

YES

Is oxygen and nutrient supply still adequate?

[from G.Stamatakos, D.Dionysiou, E.Zacharaki, N.Mouravliansky, K.Nikita, and N.Uzunoglu, "In Silico Radiation Oncology: Combining

Novel Simulation Algorithms with Current Visualization Techniques,'' Proc. IEEE, Special Issue on "Bioinformatics: Advances and Challenges" Vol.90, No.11, November 2002, pp.1764-1777] 29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 45

Irradiation according to the standard fractionation scheme

(2 Gy once a day, 5 days per week, 60 Gy in total). Left panel: three dimensional sections of the tumour shown in the right panel: (a) before the beginning of irradiation, (b) 1 fictitious day after the beginning of irradiation, (c) 2 fictitious days after the beginning of irradiation and (d) 3 fictitious days after the beginning of irradiation. Colour code red: proliferating cell layer, green: dormant cell layer (G0), blue: dead cell layer. The colouring criterion “99.8%” used to visualize the predictions has been defined as follows. “For a geometrical cell of the discretizing mesh, if the percentage of dead cells is lower than 99.8% then { if percentage of proliferating cells > percentage of G0 cells, then paint the geometrical cell red (proliferating cell layer), else paint the geometrical cell green (G0 cell layer) } else paint the geometrical cell blue (dead cell layer)” The values of certain parameters (e.g. cell loss) have been deliberately exaggerated in order to facilitate the demonstration of the ability of the model to simulate the shrinkage effect. [see G.Stamatakos, D.Dionysiou, E.Zacharaki, N.Mouravliansky, K.Nikita, and N.Uzunoglu, "In Silico Radiation Oncology: Combining Novel Simulation Algorithms with Current Visualization Techniques,'' Proc. IEEE, Special Issue on "Bioinformatics: Advances and Challenges" Vol.90, No.11, November 2002, pp.1764-1777]

(a) (b) (c) (d)

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 46

29 Aug. 2019 47 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology

Simulation predictions of the number of total tumour cells (mt p53 and wild type p53) for the standard fractionation scheme. An OER=3.0 has been assumed.

[see V. P Antipas, G. S Stamatakos, N. K Uzunoglu, D. D Dionysiou, R. G Dale, ” A spatio-temporal simulation model of the response of solid tumours to radiotherapy in vivo: parametric validation concerning oxygen enhancement ratio and cell cycle duration,” Phys. Med. Biol. 49 (2004) 1485–1504 [Pubmed Link: http://www.ncbi.nlm.nih.gov/entrez /query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15152687&query_hl=14] ]

29 Aug. 2019 48 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology

TWO RTOG STUDY 83-02 BRANCHES SIMULATED

• 1) AHF-48Gy:

accelerated hyperfractionation, 48Gy total dose, (1.6Gy twice daily to a total dose of 48 Gy)

• 2) HF-81.6Gy:

hyperfractionation, 81.6Gy total dose.(1.2Gy twice daily to a total dose of 81.6Gy)

29 Aug. 2019 49 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology

Number of surviving tumour cells as a function of time for a glioblastoma tumour with mutant p53 gene. AHF-48Gy: accelerated hyperfractionation, 48Gy total dose, HF-81.6Gy: hyperfractionation, 81.6Gy total dose.

29 Aug. 2019 50

4D (3D + time) visualization

AHF-48Gy HF-81.6Gy

G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology

29 Aug. 2019 51

Interactive 2D sampling planes

AHF-48Gy HF-81.6Gy

G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology

CHIC SURVEY ON HYPERMODELS

• CHIC is running a survey, where patients, physicians and

citizens can learn about hypermodels and can give their

• pinion on the usefulness of such models.
• Your feedback will help us to optimize our research results.
• The survey is available at http://www.chic-vph.eu/  Latest

Highlights

• r directly at http://chic-vph.eu/highlights/details/article/chic-
• nline-survey-on-hypermodels/
• A video demonstrating the future use of hypemodels is also

included in the survey

• Responsible: Prof. Norbert Graf, University Hospital of

Saarland

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 52

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 53

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 54

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 55

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 56

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 57

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 58

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 59

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 60

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 61

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 62

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 63

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 64

CHAPTER 18

G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 65 29 Aug. 2019

Conclusions

• Based on the partial validation results and analyses

that have been reported in CHIC, the highly innovative CHIC hypermodels and Oncosimulators appear to possess a great potential for serving as clinical decision support systems (CDS) and/or cores of future in silico trial platforms.

• However, additional retrospective validation

work for the developed hypermodels and Oncosimulators is needed in order to more fully substantiate and support their “candidacy” for undergoing validation through prospective clinical trials.

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 66

Conclusions ( cont.)

• This is a necessary step in order to definitely

assess both their clinical validity and clinical value.

• Further retrospective validation work will

be carried out by specific former CHIC partners

• n a bilateral or small partner group basis.
• Regarding the eventual prospective clinical

validation of the hypermodels, certain exploratory steps have already been taken, including focused discussions within the framework of the International Society for Pediatric Oncology (SIOP).

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 67

The BOUNCE Project

• In the context of exploitation, it is noted that

several approaches, processes, models and tools developed in the framework of the CHIC project have already been recruited for the implementation needs of the EU funded project BOUNCE under the title: “Predicting Effective Adaptation to Breast Cancer to Help Women to BOUNCE Back” (Grant Agreement 777167)

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 68

29 Aug. 2019 G.S. Stamatakos - Lecture at the Korea Institute of Science and Technology 69

Thank you